ERT Integrates Remote Biosensor Patch with eCOA
The biosensor is a disposable, wireless patch worn on the chest. Its thin, light form factor is comfortable and discreet while providing healthcare professionals access to unprecedented amounts of continuous vital sign data on their patients.
ERT, a global provider of patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, announced the integration of an innovative wearable biosensor which captures and wirelessly transmits real-time, continuous, clinical-grade biometric measurements into the ERT electronic Clinical Outcome Assessment (eCOA) system. The biosensor is a disposable, wireless patch worn on the chest. Its thin, light form factor is comfortable and discreet while providing healthcare professionals access to unprecedented amounts of continuous vital sign data on their patients. The patch contains cutting-edge sensors and electronics, along with advanced algorithm technologies, to provide continuous, clinical-grade measurements of ECG, respiratory rate, heart rate, heart rate variability, skin temperature, physical activity, posture and fall detection.
As a proof of concept, ERT is capturing patient fall detection data from the patch biosensor and using it to trigger an episodic electronic diary assessment to capture informationabout the circumstance of the fall. Sponsors can use one or more of the vital statistics as needed to support efficacy and/or safety endpoints that meet their clinical development objectives.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
